{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,6]],"date-time":"2026-11-06T13:14:55Z","timestamp":1793970895616,"version":"4.8.0"},"reference-count":27,"publisher":"American Society of Hematology","issue":"21","content-domain":{"domain":["ashpublications.org"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2023,11,14]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>Idiopathic multicentric Castleman disease (iMCD) is a rare hematologic disorder with an unknown etiology. Clinical presentation is heterogeneous, ranging from mild constitutional symptoms with lymphadenopathy to life-threatening multiorgan dysfunction. International, consensus treatment guidelines developed in 2018 relied upon a limited number of clinical trials and small case series; however, to our knowledge, real-world performance of these recommendations has not been subsequently studied. Siltuximab, a monoclonal antibody against interleukin 6 (IL6), is approved for the treatment of iMCD and recommended first-line, and tocilizumab, a monoclonal antibody directed against the IL6 receptor, is recommended when siltuximab is unavailable. Chemotherapy, rituximab, and immunomodulators are recommended as second- and third-line treatments based on limited evidence. Corticosteroid monotherapy is used by clinicians, although not recommended. Here, we draw upon the ACCELERATE Natural History Registry to inventory regimens and evaluate regimen response for 102 expert\u2013confirmed iMCD cases. Siltuximab with\/without (w\/wo) corticosteroids was associated with a 52% response, whereas corticosteroid monotherapy was associated with a 3% response. Anti-IL6\u2013directed therapy with siltuximab or tocilizumab demonstrated better response and more durability than was observed with rituximab w\/wo corticosteroids. Cytotoxic chemotherapy was associated with a 52% response and was predominantly administered in patients characterized by thrombocytopenia, anasarca, fever, renal failure\/reticulin fibrosis, and organomegaly. Our results provide evidence in support of current recommendations to administer anti-IL6 as first-line treatment, to administer cytotoxic chemotherapy in patients with severe refractory disease, and to limit corticosteroid monotherapy. Evidence remains limited for effective agents for patients who are refractory to anti-IL6\u2013directed therapy. This trial was registered at www.clinicaltrials.gov as #NCT02817997.<\/jats:p>","DOI":"10.1182\/bloodadvances.2023010745","type":"journal-article","created":{"date-parts":[[2023,9,1]],"date-time":"2023-09-01T11:26:35Z","timestamp":1693567595000},"page":"6652-6664","update-policy":"https:\/\/doi.org\/10.1182\/blood.2019cm0000","source":"Crossref","is-referenced-by-count":36,"title":["Treatment consistent with idiopathic multicentric Castleman disease guidelines is associated with improved outcomes"],"prefix":"10.1182","volume":"7","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-3736-1411","authenticated-orcid":false,"given":"Sheila K.","family":"Pierson","sequence":"first","affiliation":[{"name":"1Department of Medicine, Center for Cytokine Storm Treatment & Laboratory, Perelman School of Medicine, University of Pennsylvania, Philadelphia, PA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Megan S.","family":"Lim","sequence":"additional","affiliation":[{"name":"2Department of Pathology and Laboratory Medicine, Memorial Sloan Kettering Cancer Center, New York, NY"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gordan","family":"Srkalovic","sequence":"additional","affiliation":[{"name":"3Sparrow Herbert-Herman Cancer Center, Michigan State University College of Human Medicine, Lansing, MI"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0652-5791","authenticated-orcid":false,"given":"Joshua D.","family":"Brandstadter","sequence":"additional","affiliation":[{"name":"4Division of Hematology\/Oncology, Perelman School of Medicine, University of Pennsylvania, Philadelphia, PA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mateo","family":"Sarmiento Bustamante","sequence":"additional","affiliation":[{"name":"1Department of Medicine, Center for Cytokine Storm Treatment & Laboratory, Perelman School of Medicine, University of Pennsylvania, Philadelphia, PA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Saishravan","family":"Shyamsundar","sequence":"additional","affiliation":[{"name":"1Department of Medicine, Center for Cytokine Storm Treatment & Laboratory, Perelman School of Medicine, University of Pennsylvania, Philadelphia, PA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Natalie","family":"Mango","sequence":"additional","affiliation":[{"name":"1Department of Medicine, Center for Cytokine Storm Treatment & Laboratory, Perelman School of Medicine, University of Pennsylvania, Philadelphia, PA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Criswell","family":"Lavery","sequence":"additional","affiliation":[{"name":"1Department of Medicine, Center for Cytokine Storm Treatment & Laboratory, Perelman School of Medicine, University of Pennsylvania, Philadelphia, PA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bridget","family":"Austin","sequence":"additional","affiliation":[{"name":"1Department of Medicine, Center for Cytokine Storm Treatment & Laboratory, Perelman School of Medicine, University of Pennsylvania, Philadelphia, PA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Daisy","family":"Alapat","sequence":"additional","affiliation":[{"name":"5Department of Pathology, College of Medicine, University of Arkansas for Medical Sciences, Little Rock, AR"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mary Jo","family":"Lechowicz","sequence":"additional","affiliation":[{"name":"6Department of Hematology and Medical Oncology, Emory University School of Medicine and Winship Cancer Institute, Atlanta, GA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Adam","family":"Bagg","sequence":"additional","affiliation":[{"name":"7Department of Pathology and Laboratory Medicine, University of Pennsylvania, Philadelphia, PA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hongzhe","family":"Li","sequence":"additional","affiliation":[{"name":"8Department of Biostatistics, Epidemiology, and Informatics, Perelman School of Medicine, University of Pennsylvania, Philadelphia, PA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3609-661X","authenticated-orcid":false,"given":"Corey","family":"Casper","sequence":"additional","affiliation":[{"name":"9Access to Advanced Health Institute, Seattle, WA"},{"name":"10Department of Medicine, University of Washington, Seattle, WA"},{"name":"11Vaccine and Infectious Disease Division, Fred Hutchinson Cancer Center, Seattle, WA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Frits","family":"van Rhee","sequence":"additional","affiliation":[{"name":"12Myeloma Center, Winthrop P. Rockefeller Cancer Institute, University of Arkansas for Medical Sciences, Little Rock, AR"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7367-8184","authenticated-orcid":false,"given":"David C.","family":"Fajgenbaum","sequence":"additional","affiliation":[{"name":"1Department of Medicine, Center for Cytokine Storm Treatment & Laboratory, Perelman School of Medicine, University of Pennsylvania, Philadelphia, PA"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"234","published-online":{"date-parts":[[2023,11,1]]},"reference":[{"issue":"23","key":"2023111415103676200_bib1","doi-asserted-by":"crossref","first-page":"2255","DOI":"10.1056\/NEJMra2026131","article-title":"Cytokine storm","volume":"383","author":"Fajgenbaum","year":"2020","journal-title":"N\u00a0Engl J Med"},{"issue":"12","key":"2023111415103676200_bib2","doi-asserted-by":"crossref","first-page":"1646","DOI":"10.1182\/blood-2016-10-746933","article-title":"International, evidence-based consensus diagnostic criteria for HHV-8-negative\/idiopathic multicentric Castleman disease","volume":"129","author":"Fajgenbaum","year":"2017","journal-title":"Blood"},{"issue":"20","key":"2023111415103676200_bib3","doi-asserted-by":"crossref","first-page":"2115","DOI":"10.1182\/blood-2018-07-862334","article-title":"International, evidence-based consensus treatment guidelines for idiopathic multicentric Castleman disease","volume":"132","author":"van Rhee","year":"2018","journal-title":"Blood"},{"issue":"9","key":"2023111415103676200_bib4","doi-asserted-by":"crossref","first-page":"602","DOI":"10.1056\/NEJM199403033300904","article-title":"Brief report: alleviation of systemic manifestations of Castleman\u2019s disease by monoclonal anti-interleukin-6 antibody","volume":"330","author":"Beck","year":"1994","journal-title":"N\u00a0Engl J Med"},{"issue":"4","key":"2023111415103676200_bib5","doi-asserted-by":"crossref","first-page":"1360","DOI":"10.1182\/blood.V74.4.1360.1360","article-title":"Pathogenic significance of interleukin-6 (IL-6\/BSF-2) in Castleman\u2019s disease","volume":"74","author":"Yoshizaki","year":"1989","journal-title":"Blood"},{"issue":"10","key":"2023111415103676200_bib6","doi-asserted-by":"crossref","first-page":"1241","DOI":"10.1002\/ajh.26292","article-title":"Validated international definition of the thrombocytopenia, anasarca, fever, reticulin fibrosis, renal insufficiency, and organomegaly clinical subtype (TAFRO) of idiopathic multicentric Castleman disease","volume":"96","author":"Nishimura","year":"2021","journal-title":"Am J Hematol"},{"issue":"2","key":"2023111415103676200_bib7","doi-asserted-by":"crossref","first-page":"79","DOI":"10.3960\/jslrt.22011","article-title":"Idiopathic plasmacytic lymphadenopathy: a conceptual history along with a translation of the original Japanese article published in 1980","volume":"62","author":"Takeuchi","year":"2022","journal-title":"J\u00a0Clin Exp Hematop"},{"issue":"9","key":"2023111415103676200_bib8","doi-asserted-by":"crossref","first-page":"966","DOI":"10.1016\/S1470-2045(14)70319-5","article-title":"Siltuximab for multicentric Castleman\u2019s disease: a randomised, double-blind, placebo-controlled trial","volume":"15","author":"van Rhee","year":"2014","journal-title":"Lancet Oncol"},{"issue":"3","key":"2023111415103676200_bib9","doi-asserted-by":"crossref","first-page":"e209","DOI":"10.1016\/S2352-3026(19)30257-1","article-title":"Long-term safety of siltuximab in patients with idiopathic multicentric Castleman disease: a prespecified, open-label, extension analysis of two trials","volume":"7","author":"van Rhee","year":"2020","journal-title":"Lancet Haematol"},{"issue":"8","key":"2023111415103676200_bib10","doi-asserted-by":"crossref","first-page":"2627","DOI":"10.1182\/blood-2004-12-4602","article-title":"Humanized anti-interleukin-6 receptor antibody treatment of multicentric Castleman disease","volume":"106","author":"Nishimoto","year":"2005","journal-title":"Blood"},{"issue":"1","key":"2023111415103676200_bib11","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1111\/j.1365-2141.2004.05311.x","article-title":"The aetiology and management of Castleman disease at 50 years: translating pathophysiology to patient care","volume":"129","author":"Casper","year":"2005","journal-title":"Br J Haematol"},{"issue":"2","key":"2023111415103676200_bib12","doi-asserted-by":"crossref","first-page":"359","DOI":"10.1182\/bloodadvances.2021004441","article-title":"Epidemiology and treatment patterns of idiopathic multicentric Castleman disease in the era of IL-6-directed therapy","volume":"6","author":"Mukherjee","year":"2022","journal-title":"Blood Adv"},{"issue":"3","key":"2023111415103676200_bib13","doi-asserted-by":"crossref","first-page":"171","DOI":"10.4103\/picr.picr_62_21","article-title":"Introduction to real-world evidence studies","volume":"12","author":"Chodankar","year":"2021","journal-title":"Perspect Clin Res"},{"issue":"9","key":"2023111415103676200_bib14","doi-asserted-by":"crossref","first-page":"100158","DOI":"10.1016\/j.xcrm.2020.100158","article-title":"ACCELERATE: a patient-powered natural history study design enabling clinical and therapeutic discoveries in a rare disorder","volume":"1","author":"Pierson","year":"2020","journal-title":"Cell Rep Med"},{"issue":"13","key":"2023111415103676200_bib15","doi-asserted-by":"crossref","first-page":"1731","DOI":"10.1182\/blood.2020007599","article-title":"Real-world experience with caplacizumab in the management of acute TTP","volume":"137","author":"Dutt","year":"2021","journal-title":"Blood"},{"issue":"10","key":"2023111415103676200_bib16","doi-asserted-by":"crossref","first-page":"4451","DOI":"10.1172\/JCI126091","article-title":"Identifying and targeting pathogenic PI3K\/AKT\/mTOR signaling in IL-6-blockade-refractory idiopathic multicentric Castleman disease","volume":"129","author":"Fajgenbaum","year":"2019","journal-title":"J\u00a0Clin Invest"},{"issue":"19","key":"2023111415103676200_bib17","doi-asserted-by":"crossref","first-page":"1673","DOI":"10.1182\/blood.2019002792","article-title":"Increased mTOR activation in idiopathic multicentric Castleman disease","volume":"135","author":"Arenas","year":"2020","journal-title":"Blood"},{"issue":"Supplement 1","key":"2023111415103676200_bib18","doi-asserted-by":"crossref","first-page":"4316","DOI":"10.1182\/blood-2021-146821","article-title":"Increased mTORC2 pathway activation in lymph nodes of Imcd-Tafro","volume":"138","author":"Phillips","year":"2021","journal-title":"Blood"},{"issue":"16","key":"2023111415103676200_bib19","doi-asserted-by":"crossref","first-page":"1720","DOI":"10.1182\/blood-2018-11-884577","article-title":"Phase 2 study using oral thalidomide-cyclophosphamide-prednisone for idiopathic multicentric Castleman disease","volume":"133","author":"Zhang","year":"2019","journal-title":"Blood"},{"issue":"3","key":"2023111415103676200_bib20","doi-asserted-by":"crossref","first-page":"618","DOI":"10.1080\/10428194.2021.1999437","article-title":"A\u00a0prospective, multicenter study of bortezomib, cyclophosphamide, and dexamethasone in relapsed\/refractory iMCD","volume":"63","author":"Zhang","year":"2022","journal-title":"Leuk Lymphoma"},{"issue":"3","key":"2023111415103676200_bib21","doi-asserted-by":"crossref","first-page":"599","DOI":"10.1111\/bjh.17868","article-title":"Characteristics of thrombocytopenia, anasarca, fever, reticulin fibrosis and organomegaly syndrome: a retrospective study from a large Western cohort","volume":"196","author":"Maisonobe","year":"2022","journal-title":"Br J Haematol"},{"issue":"1","key":"2023111415103676200_bib22","doi-asserted-by":"crossref","first-page":"161","DOI":"10.1080\/14397595.2017.1366093","article-title":"Tentative diagnostic criteria and disease severity classification for Castleman disease: a report of the research group on Castleman disease in Japan","volume":"28","author":"Fujimoto","year":"2018","journal-title":"Mod Rheumatol"},{"issue":"2","key":"2023111415103676200_bib23","doi-asserted-by":"crossref","first-page":"232","DOI":"10.1111\/bjh.15588","article-title":"Predictors of response to anti-IL6 monoclonal antibody therapy (siltuximab) in idiopathic multicentric Castleman disease: secondary analyses of phase II clinical trial data","volume":"184","author":"Morra","year":"2019","journal-title":"Br J Haematol"},{"issue":"17","key":"2023111415103676200_bib24","doi-asserted-by":"crossref","first-page":"3445","DOI":"10.1182\/bloodadvances.2020004016","article-title":"Discovery and validation of a novel subgroup and therapeutic target in idiopathic multicentric Castleman disease","volume":"5","author":"Pierson","year":"2021","journal-title":"Blood Adv"},{"issue":"10286","key":"2023111415103676200_bib25","doi-asserted-by":"crossref","first-page":"1749","DOI":"10.1016\/S0140-6736(21)00674-7","article-title":"Adrenalitis and anasarca in idiopathic multicentric Castleman\u2019s disease","volume":"397","author":"Chen","year":"2021","journal-title":"Lancet"},{"issue":"48","key":"2023111415103676200_bib26","doi-asserted-by":"crossref","first-page":"e32200","DOI":"10.1097\/MD.0000000000032200","article-title":"Treatment-resistant idiopathic multicentric Castleman disease with thrombocytopenia, anasarca, fever, reticulin fibrosis, renal dysfunction, and organomegaly managed with Janus kinase inhibitors: a case report","volume":"101","author":"Kakutani","year":"2022","journal-title":"Medicine (Baltimore)"},{"issue":"1","key":"2023111415103676200_bib27","doi-asserted-by":"crossref","first-page":"7236","DOI":"10.1038\/s41467-022-34873-7","article-title":"CXCL13 is a predictive biomarker in idiopathic multicentric Castleman disease","volume":"13","author":"Pierson","year":"2022","journal-title":"Nat Commun"}],"container-title":["Blood Advances"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/ashpublications.org\/bloodadvances\/article-pdf\/7\/21\/6652\/2089178\/blooda_adv-2023-010745-main.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/ashpublications.org\/bloodadvances\/article-pdf\/7\/21\/6652\/2089178\/blooda_adv-2023-010745-main.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,11,14]],"date-time":"2023-11-14T10:11:58Z","timestamp":1699956718000},"score":1,"resource":{"primary":{"URL":"https:\/\/ashpublications.org\/bloodadvances\/article\/7\/21\/6652\/497732\/Treatment-consistent-with-idiopathic-multicentric"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,11,1]]},"references-count":27,"journal-issue":{"issue":"21","published-print":{"date-parts":[[2023,11,14]]}},"URL":"https:\/\/doi.org\/10.1182\/bloodadvances.2023010745","relation":{},"ISSN":["2473-9529","2473-9537"],"issn-type":[{"value":"2473-9529","type":"print"},{"value":"2473-9537","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,11,1]]}}}